American journal of translational research · 2025
Reversal effect of sugammadex sodium on rocuronium-induced neuromuscular blockade in patients undergoing painless tracheoscopy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Xia, Guo Hui, Wang Lu, Zhang Zexin
Аннотация
OBJECTIVE: To compare the efficacy and safety of sugammadex sodium versus neostigmine for rocuronium-induced neuromuscular blockade during painless tracheoscopy.
METHODS: A retrospective analysis was conducted in 278 consecutive patients who underwent painless tracheoscopy under rocuronium anesthesia between January 2023 and May 2024. Patients received either sugammadex (n = 125) or neostigmine (n = 153) for muscle-relaxant reversal. Outcomes evaluated included train-of-four (TOF) recovery times (TOF ≥ 0.25, 0.75, 0.9), complete reversal rates, recovery metrics (eye-opening time, post-anesthesia care unit (PACU) stay) and complication rates. Correlations between baseline characteristics and TOF recovery times were also assessed.
RESULTS: Sugammadex significantly accelerated TOF recovery (all P < 0.001) and improved complete reversal rate (P = 0.013). Eye-opening and PACU times were reduced by 35.4% and 35.8%, respectively (both P < 0.001). The incidences of hypoxemia, bradycardia, and postoperative nausea and vomiting (PONV) were also decreased (all P < 0.05). Age, body mass index (BMI), and American Society of Anesthesiologists (ASA) class were positively correlated with TOF recovery time.
CONCLUSION: In painless tracheoscopy, sugammadex sodium provides rapid and complete reversal of rocuronium, lowers postoperative complications, and improves perioperative efficiency.
METHODS: A retrospective analysis was conducted in 278 consecutive patients who underwent painless tracheoscopy under rocuronium anesthesia between January 2023 and May 2024. Patients received either sugammadex (n = 125) or neostigmine (n = 153) for muscle-relaxant reversal. Outcomes evaluated included train-of-four (TOF) recovery times (TOF ≥ 0.25, 0.75, 0.9), complete reversal rates, recovery metrics (eye-opening time, post-anesthesia care unit (PACU) stay) and complication rates. Correlations between baseline characteristics and TOF recovery times were also assessed.
RESULTS: Sugammadex significantly accelerated TOF recovery (all P < 0.001) and improved complete reversal rate (P = 0.013). Eye-opening and PACU times were reduced by 35.4% and 35.8%, respectively (both P < 0.001). The incidences of hypoxemia, bradycardia, and postoperative nausea and vomiting (PONV) were also decreased (all P < 0.05). Age, body mass index (BMI), and American Society of Anesthesiologists (ASA) class were positively correlated with TOF recovery time.
CONCLUSION: In painless tracheoscopy, sugammadex sodium provides rapid and complete reversal of rocuronium, lowers postoperative complications, and improves perioperative efficiency.